Impaired glucose tolerance (oral)
Methodology & AI Transparency ⓘ
Impaired glucose tolerance (oral) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry R73.02: Impaired glucose tolerance (oral) is managed within Diabetes & Glucose.
- 3 Typical cash cost range: Primary evaluation for Impaired glucose tolerance (oral) incorporates fasting insulin/C-peptide quantification [Impaired glucose tolerance (oral) R73.02] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Impaired glucose tolerance (oral): Fasting Plasma Glucose [Impaired glucose tolerance (oral) R73.02] (75 – 95 mg/dL (R73.02)) and Fasting Insulin [Impaired glucose tolerance (oral) R73.02].
Ask our AI Specialists anything about Impaired glucose tolerance (oral)
What Is Impaired glucose tolerance (oral)?
Recognized across U.S. clinical coding as R73.02 (Diabetes & Glucose), Impaired glucose tolerance (oral) is evaluated via fasting insulin/C-peptide quantification [Impaired glucose tolerance (oral) R73.02] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in diabetes & glucose, Impaired glucose tolerance (oral) (R73.02) involves advanced glycation end-product in Impaired glucose tolerance (oral) (R73.02: microvascular injury). progression correlates with shifts in Fasting Plasma Glucose [Impaired glucose tolerance (oral) R73.02] (75 – 95 mg/dL (R73.02)).
Common Symptoms & Clinical Signs
- • Presentation of Impaired glucose tolerance (oral) (R73.02): postprandial afternoon energy in Impaired glucose tolerance (oral) (R73.02: crashes and carbohydrate)
- • Secondary Impaired glucose tolerance (oral) clinical sign: tingling or numbness in Impaired glucose tolerance (oral) (R73.02: in toes and)
- • Symptom flares in Impaired glucose tolerance (oral) correlating with Fasting Plasma Glucose [Impaired glucose tolerance (oral) R73.02] deviation outside 75 – 95 mg/dL (R73.02)
- • Functional diabetes & glucose impact requiring fasting insulin/C-peptide quantification [Impaired glucose tolerance (oral) R73.02] evaluation (R73.02)
Impaired glucose tolerance (oral) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R73.02 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Impaired glucose tolerance (oral) R73.02] | 75 – 95 mg/dL (R73.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Impaired glucose tolerance (oral) R73.02] | 3.0 – 7.0 uIU/mL (R73.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Impaired glucose tolerance (oral) (R73.02: mg/dL)) | > 85% (R73.02) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Impaired glucose tolerance (oral)
Treatment selection for Impaired glucose tolerance (oral) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Impaired glucose tolerance (oral))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Elevated Lipoprotein(a) Predicts Recurrent heart attack in Diabetic Patients: What a 7,887-Participant Study Found Elevated Lp(a) was associated with increased risk of recurrent MI in patients with diabetes after ACS or PCI. Clinical cardiology • 2026-11-15 • Meta-Analysis | N = 7,887 | 94/100 | PMID 42965402 ↗ |
| New Insights on Early maternal DHA supplementation fails to modify clinical phenotypes associated: What a 404-Participant Study Found Daily DHA supplementation (600 mg) from early pregnancy was safe and well tolerated but did not demonstrate a statistically significant effect on clinical phenotypes of impaired placentation. Placenta • 2026-05-22 • Phase III Randomized Trial | N = 404 | 93/100 | PMID 42025271 ↗ |
| Can This Approach Help? Inside the Latest Research on Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous This prematurely ended study failed to confirm REX-001's efficacy for ulcer healing. Annals of vascular surgery • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42119725 ↗ |
| Can This Approach Help? Inside the Latest Research on Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired Three of the four participants had undergone SOT. Antimicrobial agents and chemotherapy • 2026-08-05 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42429789 ↗ |
| Can This Approach Help? Inside the Latest Research on Losartan and amlodipine in renally impaired hypertensive The treatment difference was statistically significant (P = 0.021). Kidney international. Supplement • 1998-12-15 • Randomized Controlled Trial | N = 48 | 88/100 | PMID 9839295 ↗ |
Impaired glucose tolerance (oral) Patient Community & “People Like Me” Threads
Filter Impaired glucose tolerance (oral) community threads and patient logs by age, biological sex, dosage, and treatment duration.